Day One Biopharmaceuticals, Inc. (DAWN)
| Market Cap | 2.22B |
| Revenue (ttm) | 158.18M |
| Net Income (ttm) | -107.32M |
| Shares Out | 103.32M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,988,826 |
| Open | 21.50 |
| Previous Close | 21.49 |
| Day's Range | 21.49 - 21.53 |
| 52-Week Range | 5.64 - 21.53 |
| Beta | -1.75 |
| Analysts | Buy |
| Price Target | 24.43 (+13.47%) |
| Earnings Date | May 1, 2026 |
About DAWN
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical t... [Read more]
Financial Performance
In 2025, DAWN's revenue was $158.18 million, an increase of 20.60% compared to the previous year's $131.16 million. Losses were -$107.32 million, 12.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for DAWN stock is "Buy." The 12-month stock price target is $24.43, which is an increase of 13.47% from the latest price.
News
Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S . in pediatric low-grade glioma.
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - March 6, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Day One Biopharmaceuti...
Is there any upside left in DAWN stock as it soars 65%?
Day One Biopharmaceuticals (NASDAQ: DAWN) ripped higher on Friday morning after Servier signed a definitive agreement to acquire the California-based firm for about $2.5 billion in cash. Servier's dea...
Day One Shares Surge After $2.5B Servier Deal
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares are trading higher Friday after the company announced that Servier will acquire it for $21.50 per share in cash.
Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion
Independent international pharmaceutical group Servier will buy Day One Biopharmaceuticals for a total equity value of about $2.5 billion, the companies said on Friday.
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (Nas...
Day One Biopharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Strong 2025 revenue growth was driven by OJEMDA’s launch, with new patient starts and therapy duration both increasing. Key pipeline updates are expected in 2025, including data from DAY301 and Emi-Le, while 2026 guidance targets 50% growth and further expansion into new indications.
Day One Biopharmaceuticals Earnings Call Transcript: Q4 2025
Net product revenue grew 172% year-over-year to $155.4M in 2025, driven by OJEMDA's strong adoption in PLGG. The company ended the year with $441M in cash, no debt, and reiterated 2026 revenue guidance of $225M-$250M, while advancing pipeline programs and integrating Emi-Le.
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipel...
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targ...
Day One Biopharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong 2025 performance was driven by OJEMDA's rapid adoption and revenue growth, with expansion into frontline pLGG and global markets underway. The pipeline was strengthened by the Emmy Lee acquisition and DAY301 progress, with key data updates expected in 2026.
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporat...
Day One Completes Acquisition of Mersana Therapeutics
BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therap...
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializin...
Day One Biopharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
The session highlighted strong commercial momentum for OJEMDA in pediatric glioma, supported by robust long-term data and high physician adoption. Pipeline progress includes the FIREFLY-2 trial, Day 301 ADC, and the Emi-Le program from the Mersana acquisition, all with key milestones expected by 2026.
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off the...
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializin...
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharmaceuticals (NASDAQ: DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug...
Day One Biopharmaceuticals Transcript: M&A Announcement
The acquisition brings a first-in-class ADC for rare cancers, focusing on ACC with no approved targeted therapies. The $129M cash deal plus milestone payments leverages clinical expertise and aims for rapid regulatory progress, with potential to expand into other indications.
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid ...
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval ...
Day One Biopharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 delivered record revenue and double-digit growth for OJEMDA, driven by strong adoption, durable persistence, and positive long-term data. Full-year guidance was raised to $145–$150M, with a robust cash position and expanding market presence.
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business Raising OJEMDA full-year 2025 net product revenue guidance to $145 to $150 million Three-ye...
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targ...